Orexigen inks distribution deal for Mysimba in Europe

US obesity specialist Orexigen Therapeutics (Nasdaq: OREX) today announced a distributorship agreement covering Germany, France and Austria for Mysimba (naltrexone HCl/bupropion HCl prolonged release) with Germany’s Cheplapharm Arzneimittel.

Under the terms of the agreement, Cheplapharm will be responsible for all commercialization activity and expenses.  Orexigen will supply Mysimba, which was approved by the European Commission for the management of weight in adult patients in the presence of one or more weight-related co-morbidities in 2015, to Cheplapharm for a negotiated transfer price.

"Cheplapharm's strong capabilities in weight management therapy and established relationships in the market make them an ideal partner to bring Mysimba to patients in Germany, France and Austria," said Dr Thomas Cannell, executive vice president, chief operating officer and president of global commercial products of Orexigen, adding: "With this agreement, we now have partnerships covering 48 countries worldwide. In Europe, Mysimba has now launched in 16 countries, and we expect to launch in up to eight more countries by year end."